News of Note—TapImmune, Hawaii Biotech and more

In this week's News of Note, TapImmune named a new CEO.

> Cancer vaccine biotech TapImmune named Peter Hoang as its next CEO. Release

> The University of Hawaii plus Soligenix and Hawaii Biotech won funding to work on a heat-stable Ebola vaccine candidate. Honolulu Civil Beat story

> AltImmune started enrollment on a phase 2 trial of its NasoVAX intranasal flu vaccine. Release

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.

> Duke University secured a $41.5 million grant to oversee quality for NIH-supported HIV and AIDS research. Triangle Business Journal story

> EpiVax launched a dedicated cancer vaccine company with $500,000 in seed funding. Release